Rocco Iannapollo becomes an Advisor to Cannabix Technologies
Mr. Iannapollo is a drug and alcohol subject matter expert, based in Houston, Texas and will advise Cannabix on global substance abuse programs across a range of industries. Cannabix meets with State of Colorado officials in Denver.
For immediate release. Vancouver, British Columbia, April 27, 2015:Cannabix Technologies Inc.(CSE: BLO, OTC PINK: BLOZF) (the “Company”) is pleased to report that Mr. Rocco Iannapollo has become an Advisor to Cannabix Technologies, developer of the hand-held Cannabix Marijuana Breathalyzer for law enforcement and workplace testing. Mr. Iannapollo is an expert on substance abuse programs with more than 20 years of experience in the oil and gas industry, working for fortune 50 companies. Rocco has extensive experience with supplier, employer, and DOT compliance policies and strategies. He also brings deep business acumen regarding operations and supply chain best practices. Mr. Iannapollo will advise Cannabix on global substance abuse programs in a range of industries. Mr. Iannapollo is a member of the Substance Abuse Program Administrator’s Association (SAPAA), the Drug and Alcohol Testing Industry Association (DATIA), as well as a speaker and regular contributor to the International Forum for Drug and Alcohol Testing (IFDAT).
Kal Malhi, President of Cannabix Technologies stated, “We are very pleased to have Rocco Iannapollo join our team of advisors as Cannabix develops relationships with law enforcement agencies, employers, and other industry stakeholders. It is evident from our discussions with prosecutors and law enforcement personnel that breath testing for drugs would be a preferred choice for testing in comparison to other collection methods. For example, we know that THC can be detected for up to 48 hours in oral fluid, meaning that its detection may not coincide with impairment. With this being the case, there is tremendous interest in breath testing technology to deliver a more accurate, non-invasive solution for law enforcement to detect marijuana impairment.”
Cannabix recently met with State of Colorado officials in Denver to introduce its Cannabix Marijuana Breathalyzer. The Company has been urged to register with the state’s Request for Proposal (RFP) website for potential RFPs regarding marijuana detection at roadside.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is the developer of the patent pending Cannabix Marijuana Breathalyzer for law enforcement and the workplace. The Cannabix Marijuana Breathalyzer drug-impairment recognition system is based on breath testing technology that has been developed to test individuals for recent consumption of the THC component of marijuana. Cannabix is advancing its products to enable law enforcement personnel to use this technology to enhance detection of marijuana impaired driving offences on North American roads at a time when marijuana is becoming legal in many jurisdictions. Cannabix is working to develop a drug-testing device that will detect Tetrahydrocannabinol (THC- the psychoactive component of marijuana that causes intoxication) using breath samples. The device would be used to provide detection of THC at the roadside to identify drivers intoxicated by the recent use of marijuana. The device will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous. The device is currently in Beta prototype development and testing and the Company is rapidly developing this technology.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (v) the ability of the Company to develop and market its future product; and (vi) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
Neither CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Contact
For additional information on Cannabix Technologies Inc. please visit our website at http://www.cannabixtechnologies.com or email info@cannabixtechnologies.com
